MCI826
Modify Date: 2024-01-10 00:55:47
MCI826 structure
|
Common Name | MCI826 | ||
|---|---|---|---|---|
| CAS Number | 140646-80-6 | Molecular Weight | 400.534 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H28N2O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MCI826MCI826 is a P-glycoprotein (P-gp) antagonist. |
| Name | MCI826 |
|---|---|
| Synonym | More Synonyms |
| Description | MCI826 is a P-glycoprotein (P-gp) antagonist. |
|---|---|
| Related Catalog | |
| Target |
P-glycoprotein[1] |
| In Vitro | Verapamil and cyclosporine A, first-generation modulators, and MCI826 (VX-710), a third generation P-gp modulator, are effective enhancers of C6-ceramide response in cells. Verapamil and MCI826 demonstrate weak cytotoxicity alone; however, when administered with C6-ceramide, which is only moderately cytotoxic, viability fell precipitously[1]. |
| Cell Assay | Cells are seeded in 96-well plates. Drugs (including MCI826 (VX-710)) are diluted freshly into culture medium containing 1% FBS and added to wells to a total volume of 0.2 mL, thus the final concentration of FBS during treatment is 5.5%. After addition of agents, cells are incubated at 37°C for 72 or 96 hr, and cell viability is determined using cell proliferation assay kit[1]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H28N2O3S |
| Molecular Weight | 400.534 |
| Exact Mass | 400.182068 |
| LogP | 4.87 |
| Index of Refraction | 1.628 |
| Storage condition | 2-8℃ |
| 2,2-Diethyl-4-({3-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)vinyl]phenyl}amino)-4-oxobutanoic acid |
| Butanoic acid, 2,2-diethyl-4-[[3-[(E)-2-[4-(1-methylethyl)-2-thiazolyl]ethenyl]phenyl]amino]-4-oxo- |